About the Company
Alternating electric field therapy, sometimes called tumor treating fields (TTFields), is a type of electromagnetic field therapy using low-intensity, intermediate frequency electrical fields to treat cancer. TTFields disrupt cell division by disrupting dipole alignment and inducing dielectrophoresis of critical molecules and organelles during mitosis. These anti-mitotic effects lead to cell death, slowing cancer growth. A TTField-treatment device manufactured by the Israeli company Novocure is approved in the United States and Europe for the treatment of newly diagnosed and recurrent glioblastoma, malignant pleural mesothelioma (MPM), and is undergoing clinical trials for several other tumor types. Despite earning regulatory approval, the efficacy of this technology remains controversial among medical experts.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
1224
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on NovoCure Ltd
Here's Why NovoCure Ltd. Is Skyrocketing Today - Fox Business
He Made 21,078% Buying Amazon. Heres His New Pick NovoCure gave a series of clinical updates that got the markets excited. First, the company reported data from its phase 2 Panova study.
Novocure Ltd (NVCR) - News - Insider Monkey
NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript NovoCure Limited beats earnings expectations. Reported EPS is $-0.36134, expectations were $-0.43. Keep Reading → ...
Novocure's lung cancer device study raises concerns around ... - Yahoo
(Reuters) -Novocure Ltd's experimental device to treat a type of lung cancer helped in extending overall survival among patients in a late-stage study, but concerns around its commercial success ...
NovoCure Ltd (038.SG) - Yahoo Finance
NovoCure ( NASDAQ:NVCR ) Second Quarter 2025 Results Key Financial Results Revenue: US$158.8m (up 5.6% from 2Q 2024... ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $40 ...
Baillie Gifford & Co Cuts Stake in Novocure Ltd (NVCR)
Fintel reports that Baillie Gifford & Co has filed a 13G/A form with the SEC disclosing ownership of 8,863,842 shares of Novocure Ltd (NVCR). This represents 8.45% of the company.
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue ...
NovoCure Ltd (NVCR) reports a 22% revenue increase and FDA approvals, while navigating executive changes and reimbursement challenges.
Here's Why NovoCure Ltd. Is Skyrocketing Today - The Motley Fool
Finally, NovoCure announced data from its long-term EF-14 trial as well. This 695-patient study was designed to test the long-term outcomes of using Optune in combination with temozolomide ...
Novocure Ltd (NVCR) CEO Asaf Danziger on Q3 2020 Results - Earnings ...
Novocure Ltd (NASDAQ: NVCR) Q3 2020 Earnings Conference Call October 29, 2020 8:00 AM ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger ...
Novocure Ltd. Company & People | NVCR | Barron's
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor ...
038 | Novocure Ltd. Profile | MarketWatch
Company Profile Novocure Ltd. No. 4 The Forum Grenville Street 2nd Floor St. Helier, Jersey JE2 4UF Phone44 15 347-56700 ...
Investors Eyeing NovoCure’s Ovarian Cancer Treatment Trials
The global oncology company NovoCure Ltd (NASDAQ: NVCR), which is focused on the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields), has been in the ...
Novocure Ltd (NVCR) CEO Asaf Danziger on Q2 2022 Results - Earnings ...
Novocure Ltd (NVCR) CEO Asaf Danziger on Q2 2022 Results - Earnings Call Transcript Jul. 28, 2022 11:54 AM ET NovoCure Limited (NVCR) Stock NVCR SA Transcripts 154.02K Follower s ...
Similar Companies
Loading the latest forecasts...